Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma

Key Inclusion Criteria:

1. Histologically confirmed diagnosis of MCL

2. Prior systemic treatments for MCL (at least one line of anti-cluster ofdifferentiation 20 (anti-CD20) based immune or chemoimmunotherapy and at least onekind of covalent or non-covalent adequate Bruton Tyrosine Kinase (BTK) inhibitor).

3. Relapsed/refractory disease

4. Presence of measurable disease

5. Availability of archival tissue confirming diagnosis of MCL, or willing to undergofresh tumor biopsy

6. Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2.

7. Adequate organ function

Key Exclusion Criteria:

1. Known central nervous system involvement by lymphoma

2. Prior malignancy other than MCL within the past 3 years, except for curativelytreated basal or squamous cell skin cancer, superficial bladder cancer, carcinoma insitu of the cervix or breast, or localized Gleason score 6 prostate cancer.

3. Prior exposure to a BCL-2 inhibitor (eg, venetoclax/ABT-199).

4. Prior autologous stem cell transplant within the last 3 months; or prior autologouschimeric antigen receptor T-cell therapy within the last 3 months; or priorallogeneic stem cell transplant within the last 6 months or currently has an activegraft-vs-host disease requiring the use of immunosuppressants.

5. Clinically significant cardiovascular disease.

6. Major surgery or significant injury ≤ 4 weeks prior to start of study treatment.

7. Active fungal, bacterial or viral infection requiring systemic treatment.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.